Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000407342

Medchemexpress LLC Mianserin hydrochloride | 21535-47-7 | 99.95% | 1 G
SDP

Catalog No. 5000407342
Encompass_Preferred

Mianserin hydrochloride is an orally active H1 receptor antagonist that can activate κ-opioid and octapamine receptors. It increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and dynorphin A-induced MAPK phosphorylation. This compound modulates social and exploratory behaviour, raises electroconvulsive thresholds, and can be used for research of neurological diseases, including depression and epilepsy.

  • Orally active H1 receptor antagonist
  • Activates κ-opioid and octapamine receptors
  • Increases ERK1/2 and CREB phosphorylation
  • Antagonizes full κ-opioid agonist and dynorphin A-induced MAPK phosphorylation
  • Modulates social and exploratory behaviour
  • Raises electroconvulsive thresholds
  • Used for research of neurological diseases, such as depression and epilepsy

Catalog No. 50-004-07342 Supplier Medchemexpress LLC Supplier No. HYB0188A1G
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Mianserin hydrochloride is an orally active H1 receptor antagonist that can activate κ-opioid and octapamine receptors. It increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and dynorphin A-induced MAPK phosphorylation. This compound modulates social and exploratory behaviour, raises electroconvulsive thresholds, and can be used for research of neurological diseases, including depression and epilepsy.

  • Orally active H1 receptor antagonist
  • Activates κ-opioid and octapamine receptors
  • Increases ERK1/2 and CREB phosphorylation
  • Antagonizes full κ-opioid agonist and dynorphin A-induced MAPK phosphorylation
  • Modulates social and exploratory behaviour
  • Raises electroconvulsive thresholds
  • Used for research of neurological diseases, such as depression and epilepsy

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.